Biologic medicines in gastroenterology      

FOI REFERENCE: 24149 FOI DATE: 5^th June 2024   

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

• Adalimumab – Humira                                12
• Adalimumab Biosimilar                               155    
• Etrasimod                                                    0
• Filgotinib                                                      *
• Golimumab                                                  *  
• Infliximab – Remicade                                 0
• Infliximab Biosimilar                                    319
• Mirikizumab                                                 0
• Ozanimod                                                    0
• Risankizumab                                              *
• Tofacitinib                                                    18
• Upadacitinib                                                 14
• Ustekinumab                                                101
• Vedolizumab                                                121

*This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018